

## Special Issue

# Mechanisms of Immunosuppression in Cancer

### Message from the Guest Editor

Tumor-induced immunosuppression hampers and modulates the activity of cytotoxic T cells and NK cells through the secretion of various cytokines and metabolites, and recruitment of immunosuppressive cells such as myeloid-derived suppressor cells, tumor-associated macrophages, regulatory T cells, and regulatory B cells. Hence, it is crucial to understand various tumor-induced immunosuppressive mechanisms to design and develop effective novel immunotherapies and to refine approaches to improve currently available immunotherapies. This Special Issue invites original research articles and review articles to address the mechanisms of tumor-induced immunosuppression, major impediments for effective antitumor immunity, and approaches to convert ‘cold tumors’ into ‘hot tumors’, which are focused on but not limited to the reprogramming of immune cells, novel immune checkpoints, normalizing tumor vasculature, cytokine modulation, metabolic intervention, targeting exosomes, and strategies to block the infiltration of immunosuppressive cells in the tumor bed.

### Guest Editor

Dr. Shweta Joshi

Department of Pediatrics, Moores Cancer Center, University of California, San Diego, CA, USA

### Deadline for manuscript submissions

closed (30 December 2023)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/126571](https://mdpi.com/si/126571)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)